Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATL1103 in acromegaly
ACTRN12615000289516Phase 2Completed
- Sponsor
- Percheron Therapeutics Ltd
- Start
- Aug 2015
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atesidorsen in acromegaly, sponsored by Percheron Therapeutics Ltd. Primary endpoints: Safety and tolerability and Single and multiple dose pharmacokinetics. Started Aug 2015; status: completed.
02
Drugs
atesidorsen
03
Conditions
acromegaly
Beyond the preview
Go deeper on ACTRN12615000289516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000289516.